Christiane Querfeld

List of Publications by Year
in descending order

103	3,919	147801	133252
papers	citations	31 h-index	59 g-index

104	104	104	3463
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1192-1204.	10.7	398
2	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÃ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	1.6	328
3	Primary cutaneous T-cell lymphoma (mycosis fungoides and SÃ©zary syndrome). Journal of the American Academy of Dermatology, 2014, 70, 205.e1-205.e16.	1.2	287
4	Primary cutaneous T-cell lymphoma (mycosis fungoides and SÃ©zary syndrome). Journal of the American Academy of Dermatology, 2014, 70, 223.e1-223.e17.	1.2	249
5	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunology Research, 2016, 4, 383-389.	3.4	247
6	SÃ©zary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology, 2011, 64, 352-404.	1.2	154
7	Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy. Archives of Dermatology, 2005, 141, 305-311.	1.4	139
8	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research, 2021, 27, 2190-2199.	7.0	110
9	Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leukemia and Lymphoma, 2009, 50, 1969-1976.	1.3	102
10	Outcome of Patients Treated With a Single-Fraction Dose of Palliative Radiation for Cutaneous T-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2013, 85, 747-753.	0.8	91
11	The Selective Protein Kinase C Î² Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines through the AKT Pathway. Journal of Investigative Dermatology, 2006, 126, 1641-1647.	0.7	89
12	Pembrolizumab-associated sarcoidosis. JAAD Case Reports, 2016, 2, 290-293.	0.8	80
13	Targeting CD47 in SÃ©zary syndrome with SIRPÎ±Fc. Blood Advances, 2019, 3, 1145-1153.	5.2	77
14	Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and SÃ©zary syndrome. Blood, 2014, 123, 1159-1166.	1.4	76
15	Primary cutaneous B-cell lymphomas. Journal of the American Academy of Dermatology, 2013, 69, 343.e1-343.e11.	1.2	73
16	Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunology Research, 2018, 6, 900-909.	3.4	73
17	Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology, 2014, 46, 610-616.	0.6	55
18	Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. Current Opinion in Oncology, 2018, 30, 332-337.	2.4	55

#	Article	IF	Citations
19	Tumor microenvironment in mycosis fungoides and SÃ©zary syndrome. Current Opinion in Oncology, 2016, 28, 88-96.	2.4	53
20	Progression of undiagnosed cutaneous lymphoma after antiâ€“tumor necrosis factor-alpha therapy. Journal of the American Academy of Dermatology, 2018, 78, 1068-1076.	1.2	46
21	Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	44
22	Comparison of selective retinoic acid receptorâ€“ and retinoic X receptorâ€“mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. Journal of the American Academy of Dermatology, 2004, 51, 25-32.	1.2	43
23	Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or SÃ©zary syndrome: a multicentre, phase 1 study. Lancet Haematology,the, 2021, 8, e808-e817.	4.6	42
24	Primary cutaneous lymphomas: a review with current treatment options. Blood Reviews, 2003, 17, 131-142.	5.7	40
25	Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opinion on Pharmacotherapy, 2006, 7, 907-915.	1.8	40
26	Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. , 2021, 9, e002022.		40
27	Hematopoietic Stem Cell Transplant for Mycosis Fungoides and SÃ©zary Syndrome. Dermatologic Clinics, 2015, 33, 807-818.	1.7	39
28	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. British Journal of Dermatology, 2021, 184, 722-730.	1.5	39
29	Multicenter Case Series of Indolent Small/Medium-Sized CD8+ Lymphoid Proliferations With Predilection for the Ear and Face. American Journal of Dermatopathology, 2014, 36, 402-408.	0.6	38
30	Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Management and Research, 2012, 4, 75.	1.9	35
31	Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: A single-center, retrospective study. Journal of the American Academy of Dermatology, 2015, 72, 293-301.e2.	1.2	35
32	Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology, 2010, 24, 574-87.	0.5	35
33	The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Current Opinion in Hematology, 2005, 12, 273-278.	2.5	32
34	Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1474-1480.	1.3	32
35	Longâ€term followâ€up and management of small and mediumâ€sized <scp>CD</scp>4⁺ T cell lymphoma and <scp>CD</scp>8⁺ lymphoid proliferations of acral sites: a multicenter experience. International Journal of Dermatology, 2016, 55, 1248-1254.	1.0	31
36	Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/SÃ©zary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins. Clinical Cancer Research, 2011, 17, 5748-5754.	7.0	29

#	Article	IF	Citations
37	Clinical Outcome and Prognosis of Young Patients with Mycosis Fungoides. Pediatric Dermatology, 2017, 34, 547-553.	0.9	25
38	The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal of Clinical Dermatology, 2021, 22, 407-414.	6.7	24
39	Sorafenib-induced eruption resembling pityriasis rubra pilaris. Journal of the American Academy of Dermatology, 2011, 65, 452-453.	1.2	23
40	Reflectance confocal microscopy features of mycosis fungoides and SÃ©zary syndrome: correlation with histopathologic and Tâ€cell receptor rearrangement studies. Journal of Cutaneous Pathology, 2016, 43, 505-515.	1.3	23
41	Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2021, 141, 1601-1604.e2.	0.7	22
42	Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients. Blood, 2017, 130, 820-820.	1.4	22
43	Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. Journal of the American Academy of Dermatology, 2020, 83, 928-930.	1.2	21
44	Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series. British Journal of Dermatology, 2022, 186, 153-166.	1.5	20
45	Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma. Blood, 2018, 132, 2903-2903.	1.4	20
46	Targeting macrophages for enhancing CD47 blockadeâ€“elicited lymphoma clearance and overcoming tumor-induced immunosuppression. Blood, 2022, 139, 3290-3302.	1.4	20
47	Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and SÃ©zary syndrome. Journal of the American Academy of Dermatology, 2007, 56, 580-583.	1.2	18
48	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and SÃ©zary Syndrome. American Journal of Surgical Pathology, 2018, 42, 726-734.	3.7	17
49	Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. British Journal of Haematology, 2017, 176, 16-36.	2.5	16
50	Multi-Kinase Inhibitor with Anti-p38Î³ Activity in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2018, 138, 2377-2387.	0.7	16
51	Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review. Current Hematologic Malignancy Reports, 2020, 15, 333-342.	2.3	15
52	Graftâ€versusâ€host diseaseâ€like erythroderma: a manifestation of thymomaâ€associated multiorgan autoimmunity. Journal of Cutaneous Pathology, 2015, 42, 663-668.	1.3	13
53	Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin. JAMA Dermatology, 2016, 152, 1388.	4.1	12
54	Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large Bâ€cell lymphoma, leg type. British Journal of Haematology, 2019, 187, e79-e82.	2.5	12

#	Article	IF	Citations
55	Cutaneous Hemophagocytosis After Alemtuzumab Injection in a Patient With SÃ©zary Syndrome. JAMA Dermatology, 2014, 150, 1021.	4.1	11
56	Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPÎ±Fc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and SÃ©zary Syndrome: Interim Results of a Multicenter Phase I Trial. Blood, 2018, 132, 1653-1653.	1.4	11
57	High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Advances, 2022, 6, 452-459.	5.2	11
58	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood, 2021, 138, 2435-2440.	1.4	10
59	Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome. Cancer Treatment and Research, 2019, 176, 225-248.	0.5	9
60	CD30-Positive Lymphoproliferative Disorders. Cancer Treatment and Research, 2019, 176, 249-268.	0.5	9
61	Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IAâ€“IIA Mycosis Fungoides. Dermatology, 2022, 238, 347-357.	2.1	9
62	MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma. Journal of Investigative Dermatology, 2022, 142, 603-612.e7.	0.7	9
63	Integrating novel systemic therapies for the treatment of mycosis fungoides and SÃ©zary syndrome. Best Practice and Research in Clinical Haematology, 2018, 31, 322-335.	1.7	8
64	Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash. JAAD Case Reports, 2021, 14, 37-42.	0.8	8
65	Expression of immune checkpoint molecules programmed death protein 1, programmed deathâ€ligand 1 and inducible Tâ€cell coâ€stimulator in mycosis fungoides and SÃ©zary syndrome: association with disease stage and clinical outcome*. British Journal of Dermatology, 2022, 187, 234-243.	1.5	8
66	Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous TÂCell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings. Advances in Therapy, 2022, 39, 3979-4002.	2.9	8
67	Targeting microRNA in hematologic malignancies. Current Opinion in Oncology, 2020, 32, 535-544.	2.4	7
68	Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides. Cancers, 2021, 13, 5854.	3.7	7
69	Disseminated Mantle-Cell Lymphoma Presenting as a Petechial Maculopapular Eruption. JAMA Dermatology, 2014, 150, 94.	4.1	6
70	Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile. Blood, 2019, 134, 4024-4024.	1.4	6
71	Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and SÃ©zary syndrome. Best Practice and Research in Clinical Haematology, 2019, 32, 239-252.	1.7	5
72	The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas. Supportive Care in Cancer, 2021, 29, 6669-6679.	2.2	5

#	Article	IF	Citations
73	Mycosis fungoidesâ€derived exosomes promote cell motility and are enriched with microRNAâ€155 and microRNAâ€1246, and their plasmaâ€cellâ€free expression may serve as a potential biomarker for disease burden. British Journal of Dermatology, 2021, 185, 999-1012.	1.5	5
74	T Cells in CTCL Have an Exhausted Phenotype While Cutaneous Dendritic Cells Display a Normally Activated Mature Phenotype. Blood, 2014, 124, 1695-1695.	1.4	5
75	Cutaneous T-Cell lymphomas: a review with emphasis on new treatment approaches. Seminars in Cutaneous Medicine and Surgery, 2003, 22, 150-161.	1.6	4
76	Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: A phase 2 extension study. Journal of the American Academy of Dermatology, 2021, , .	1.2	4
77	A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.. Journal of Clinical Oncology, 2017, 35, TPS3101-TPS3101.	1.6	4
78	Graftâ€versusâ€host diseaseâ€like erythroderma: a manifestation of thymomaâ€associated multiorgan autoimmunity. Journal of Cutaneous Pathology, 2015, 42, 923-928.	1.3	3
79	The emerging role of micro<scp>RNA</scp>s in the molecular diagnosis of mycosis fungoides. British Journal of Dermatology, 2019, 180, 984-985.	1.5	3
80	Safety of Mogamulizumab in Mycosis Fungoides and SÃ©zary Syndrome: Final Results from the Phase 3 Mavoric Study. Blood, 2019, 134, 5300-5300.	1.4	3
81	Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL. Blood, 2011, 118, 1638-1638.	1.4	3
82	Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.. Blood, 2012, 120, 2735-2735.	1.4	3
83	Emerging drugs for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Emerging Drugs, 2022, 27, 45-54.	2.4	3
84	Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders. JID Innovations, 2022, 2, 100068.	2.4	2
85	Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial. Blood, 2020, 136, 37-37.	1.4	2
86	TnfÎ± Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression. Blood, 2020, 136, 33-34.	1.4	2
87	Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data. American Journal of Clinical Dermatology, 2022, 23, 561-570.	6.7	2
88	Mechanisms of resistance to mogamulizumab. Blood, 2022, 139, 3674-3676.	1.4	2
89	The regulation of PD-L1 expression by miRNAs in cutaneous T-cell lymphoma. European Journal of Cancer, 2018, 101, S9.	2.8	1
90	PHASE 1/2 TRIAL OF ANTI-PD-LIGAND 1 (DURVALUMAB) +/- LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: PRELIMINARY RESULTS OF PHASE 1 AND CORRELATIVE STUDIES. Hematological Oncology, 2019, 37, 519-520.	1.7	1

#	Article	IF	Citations
91	The great masquerader mimicking plasma cell myeloma. Blood, 2019, 134, 1481-1481.	1.4	1
92	Role of p38Î³ - NFATc4 - IL17A Pathway As a Potential Therapeutic Target in Cutaneous T Cell Lymphoma. Blood, 2016, 128, 2725-2725.	1.4	1
93	High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma. Blood, 2015, 126, 1485-1485.	1.4	1
94	Phase 1/2 Trial of Durvalumab and Lenalidomide in Patients with Cutaneous T Cell Lymphoma (CTCL): Preliminary Results of Phase I Results and Correlative Studies. Blood, 2018, 132, 2931-2931.	1.4	1
95	Diagnostic and therapeutic challenges of primary cutaneous lymphomas. Oncology, 2009, 23, 1167-8.	0.5	1
96	Local Lymph Node Micrometastasis in a Patient With Negative Sentinel Lymph Node Biopsies After Lymphatic Mapping With Wide Local Excision of Primary Melanoma on the Head/Neck Area. American Journal of Dermatopathology, 2011, 33, 745-748.	0.6	0
97	Tenâ€year pruritic eruption in a Japanese man. International Journal of Dermatology, 2015, 54, 635-636.	1.0	0
98	Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center.. Blood, 2012, 120, 2643-2643.	1.4	0
99	Dissecting the Roles of p38Î² and p38Î³ in Cutaneous T Cell Lymphoma. Blood, 2018, 132, 2866-2866.	1.4	0
100	Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders. Blood, 2021, 138, 4487-4487.	1.4	0
101	In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases. Blood, 2021, 138, 4383-4383.	1.4	0
102	The Involvement of STAT/SOCS Signaling in miRNA-Induced T Cell Exhaustion in Cutaneous T-Cell Lymphoma. Blood, 2020, 136, 1-1.	1.4	0
103	Mycosis fungoides and SÃ©zary syndrome. , 0, , 432-448.		0